Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

14.42USD
23 Apr 2018
Change (% chg)

$0.39 (+2.78%)
Prev Close
$14.03
Open
$14.13
Day's High
$14.75
Day's Low
$14.05
Volume
119,238
Avg. Vol
322,165
52-wk High
$27.07
52-wk Low
$8.36

Chart for

About

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria... (more)

Overall

Beta: 3.63
Market Cap(Mil.): $677.45
Shares Outstanding(Mil.): 48.29
Dividend: --
Yield (%): --

Financials

  OMER.OQ Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -1.18 -- --
ROI: -75.74 -0.74 13.21
ROE: -- -2.80 15.01

BRIEF-Omeros Announces Amendment Of Credit Facility

* AMENDED ITS EXISTING CREDIT FACILITY WITH CERTAIN AFFILIATES OF CRG LP

Apr 11 2018

BRIEF-Omeros Q4 Loss Per Share $0.34

* Q4 REVENUE $13.8 MILLION Source text for Eikon: Further company coverage:

Mar 01 2018

BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721

* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY

Jan 22 2018

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

Jan 03 2018

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS

Dec 12 2017

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

Nov 09 2017

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

Oct 26 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.83 +0.17
Novartis AG (NOVN.S) CHF76.04 -0.04
Pfizer Inc. (PFE.N) $36.80 +0.17
Roche Holding Ltd. (ROG.S) CHF217.60 +1.95
Roche Holding Ltd. (RO.S) CHF221.40 +1.40
Merck & Co., Inc. (MRK.N) $60.25 +1.42
Bayer AG (BAYGn.DE) €98.79 -0.21
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.71 +0.43
Eli Lilly And Co (LLY.N) $80.20 +1.14

Earnings vs. Estimates